Angiodynamic Expects FY2024 Sales Of $270M-$275M, Reflects PICC And Midline Businesses Divestiture And Discontinuance Of RadioFrequency Ablation And Syntrax Businesses, Which Accounted For ~$50M Of Prior Guidance Of $320M-$325M Vs. Consensus Of $312.14M
Angiodynamic Expects FY2024 Sales Of $270M-$275M, Reflects PICC And Midline Businesses Divestiture And Discontinuance Of RadioFrequency Ablation And Syntrax Businesses, Which Accounted For ~$50M Of Prior Guidance Of $320M-$325M Vs. Consensus Of $312.14M
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.